These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36402703)

  • 1. Influence of Iron Deficiency on Clinical and Haemodynamic Parameters in Pulmonary Arterial Hypertension Cohorts.
    Saluja P; Gautam N; Amisha F; Salah HM; Smith J; Biyani S; Venkata AN; Al'Aref SJ; Jagana R
    Heart Lung Circ; 2022 Dec; 31(12):1594-1603. PubMed ID: 36402703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serial Measurements of N-Terminal Pro-B-Type Natriuretic Peptide Serum Level for Monitoring Pulmonary Arterial Hypertension in Children.
    Said F; Haarman MG; Roofthooft MTR; Hillege HL; Ploegstra MJ; Berger RMF
    J Pediatr; 2020 May; 220():139-145. PubMed ID: 32113658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study.
    Thakkar V; Stevens WM; Prior D; Moore OA; Byron J; Liew D; Patterson K; Hissaria P; Roddy J; Zochling J; Sahhar J; Nash P; Tymms K; Celermajer D; Gabbay E; Youssef P; Proudman SM; Nikpour M
    Arthritis Res Ther; 2012 Jun; 14(3):R143. PubMed ID: 22691291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of right ventricular Tei-index for assessing disease severity and determining response to treatment in patients with pulmonary arterial hypertension.
    Ogihara Y; Yamada N; Dohi K; Matsuda A; Tsuji A; Ota S; Ishikura K; Nakamura M; Ito M
    J Cardiol; 2014 Feb; 63(2):149-53. PubMed ID: 24012334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Right Heart Network and Risk Stratification in Pulmonary Arterial Hypertension.
    Haddad F; Contrepois K; Amsallem M; Denault AY; Bernardo RJ; Jha A; Taylor S; Arthur Ataam J; Mercier O; Kuznetsova T; Vonk Noordegraaf A; Zamanian RT; Sweatt AJ
    Chest; 2022 May; 161(5):1347-1359. PubMed ID: 34774527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide in pediatric patients with pulmonary arterial hypertension.
    Takatsuki S; Wagner BD; Ivy DD
    Congenit Heart Dis; 2012; 7(3):259-67. PubMed ID: 22325151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan.
    Rotondo C; Praino E; Nivuori M; di Serio F; Lapadula G; Iannone F
    Int J Rheum Dis; 2017 Jan; 20(1):90-96. PubMed ID: 26218502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Risk factors for death and the clinical features of different subtypes of patients with pulmonary arterial hypertension related to congenital heart disease].
    Xu ZY; Li QQ; Zhang C; Zhang HS; Gu H
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Apr; 48(4):315-322. PubMed ID: 32370483
    [No Abstract]   [Full Text] [Related]  

  • 9. The Role of Noninvasive Endpoints in Predicting Long-Term Outcomes in Pulmonary Arterial Hypertension.
    Wronski SL; Mordin M; Kelley K; Anguiano RH; Classi P; Shen E; Manaker S
    Lung; 2020 Feb; 198(1):65-86. PubMed ID: 31722043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension.
    Rhodes CJ; Wharton J; Howard LS; Gibbs JS; Wilkins MR
    Heart; 2011 Jul; 97(13):1054-60. PubMed ID: 21558476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment goals of pulmonary hypertension.
    McLaughlin VV; Gaine SP; Howard LS; Leuchte HH; Mathier MA; Mehta S; Palazzini M; Park MH; Tapson VF; Sitbon O
    J Am Coll Cardiol; 2013 Dec; 62(25 Suppl):D73-81. PubMed ID: 24355644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of changes in NT-proBNP, hsTnT and uric acid levels with haemodynamic changes after targeted medical therapies in patients with idiopathic pulmonary arterial hypertension.
    Li WT; Wu CW; Liu JM
    Cardiovasc J Afr; 2022 Jan-Feb 23; 33(1):10-14. PubMed ID: 34851353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokines as prognostic biomarkers in pulmonary arterial hypertension.
    Boucly A; Tu L; Guignabert C; Rhodes C; De Groote P; Prévot G; Bergot E; Bourdin A; Beurnier A; Roche A; Jevnikar M; Jaïs X; Montani D; Wilkins MR; Humbert M; Sitbon O; Savale L
    Eur Respir J; 2023 Mar; 61(3):. PubMed ID: 36549710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry.
    Chung L; Fairchild RM; Furst DE; Li S; Alkassab F; Bolster MB; Csuka ME; Derk CT; Domsic RT; Fischer A; Frech TM; Gomberg-Maitland M; Gordon JK; Hinchcliff M; Hsu V; Hummers LK; Khanna D; Medsger TAJ; Molitor JA; Preston IR; Schiopu E; Shapiro L; Hant F; Silver R; Simms R; Varga J; Steen VD; Zamanian RT
    Clin Exp Rheumatol; 2017; 35 Suppl 106(4):106-113. PubMed ID: 27908301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haemodynamic effects of PAH-targeted therapies in pulmonary hypertension due to lung disease: A systematic review and meta-analysis.
    Farmakis IT; Vazakidis P; Doundoulakis I; Arvanitaki A; Zafeiropoulos S; Boutou A; Karvounis H; Giannakoulas G
    Pulm Pharmacol Ther; 2021 Jun; 68():102036. PubMed ID: 33979684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Echocardiography in pediatric pulmonary arterial hypertension: early study on assessing disease severity and predicting outcome.
    Ploegstra MJ; Roofthooft MT; Douwes JM; Bartelds B; Elzenga NJ; van de Weerd D; Hillege HL; Berger RM
    Circ Cardiovasc Imaging; 2015 Jan; 8(1):. PubMed ID: 25552488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-Life Experience with Selexipag as an Add-On Therapy to Oral Combination Therapy in Patients with Pulmonary Arterial or Distal Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Analysis.
    Berlier C; Schwarz EI; Saxer S; Lichtblau M; Ulrich S
    Lung; 2019 Jun; 197(3):353-360. PubMed ID: 30963265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysis.
    Hoeper MM; Pausch C; Olsson KM; Huscher D; Pittrow D; Grünig E; Staehler G; Vizza CD; Gall H; Distler O; Opitz C; Gibbs JSR; Delcroix M; Ghofrani HA; Ewert R; Kaemmerer H; Kabitz HJ; Skowasch D; Behr J; Milger K; Halank M; Wilkens H; Seyfarth HJ; Held M; Dumitrescu D; Tsangaris I; Vonk-Noordegraaf A; Ulrich S; Klose H; Claussen M; Eisenmann S; Schmidt KH; Rosenkranz S; Lange TJ
    J Heart Lung Transplant; 2022 Jul; 41(7):971-981. PubMed ID: 35430147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study.
    Thakkar V; Stevens W; Prior D; Youssef P; Liew D; Gabbay E; Roddy J; Walker JG; Zochling J; Sahhar J; Nash P; Lester S; Rischmueller M; Proudman SM; Nikpour M
    Arthritis Res Ther; 2013; 15(6):R193. PubMed ID: 24246100
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.